{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:45:41Z","timestamp":1790419541544,"version":"4.1.0"},"reference-count":48,"publisher":"The Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,1]]},"DOI":"10.1210\/jc.2011-3060","type":"journal-article","created":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:13:53Z","timestamp":1333239233000},"page":"1871-1880","source":"Crossref","is-referenced-by-count":238,"title":["Comparative Effectiveness of Drug Treatments to Prevent Fragility Fractures: A Systematic Review and Network Meta-Analysis"],"prefix":"10.1210","volume":"97","author":[{"given":"Mohammad Hassan","family":"Murad","sequence":"first","affiliation":[{"name":"Knowledge and Evaluation Research Unit (M.H.M., R.J.M., L.M.S., M.A.L., N.O.A.E., V.M.M.), Rochester, Minnesota 55905"},{"name":"Division of Preventive Medicine (M.H.M.), Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Drake","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, Nutrition (M.T.D., V.M.M.), Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Mullan","sequence":"additional","affiliation":[{"name":"Knowledge and Evaluation Research Unit (M.H.M., R.J.M., L.M.S., M.A.L., N.O.A.E., V.M.M.), Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen F.","family":"Mauck","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine (K.F.M.), Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise M.","family":"Stuart","sequence":"additional","affiliation":[{"name":"Knowledge and Evaluation Research Unit (M.H.M., R.J.M., L.M.S., M.A.L., N.O.A.E., V.M.M.), Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie A.","family":"Lane","sequence":"additional","affiliation":[{"name":"Knowledge and Evaluation Research Unit (M.H.M., R.J.M., L.M.S., M.A.L., N.O.A.E., V.M.M.), Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisrin O.","family":"Abu Elnour","sequence":"additional","affiliation":[{"name":"Knowledge and Evaluation Research Unit (M.H.M., R.J.M., L.M.S., M.A.L., N.O.A.E., V.M.M.), Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia J.","family":"Erwin","sequence":"additional","affiliation":[{"name":"Mayo Clinic Libraries (P.J.E.), Mayo Clinic, Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Hazem","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (A.H.), University of North Dakota, Fargo, North Dakota 58102"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo A.","family":"Puhan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology (M.A.P., T.L.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Epidemiology (M.A.P., T.L.), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Montori","sequence":"additional","affiliation":[{"name":"Knowledge and Evaluation Research Unit (M.H.M., R.J.M., L.M.S., M.A.L., N.O.A.E., V.M.M.), Rochester, Minnesota 55905"},{"name":"Division of Endocrinology, Diabetes, Metabolism, Nutrition (M.T.D., V.M.M.), Rochester, Minnesota 55905"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113223930000_B1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/PL00004156","article-title":"Epidemiology of osteoporosis.","volume":"9","author":"Cooper","year":"1999","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113223930000_B2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.beem.2008.06.001","article-title":"Epidemiology of osteoporosis.","volume":"22","author":"Holroyd","year":"2008","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113223930000_B3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7326\/0003-4819-148-3-200802050-00198","article-title":"Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis.","volume":"148","author":"MacLean","year":"2008","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041113223930000_B4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1741-7015-9-79","article-title":"Network meta-analysis\u2014highly attractive but more methodological research is needed.","volume":"9","author":"Li","year":"2011","journal-title":"BMC Med"},{"key":"key\n\t\t\t\t2019041113223930000_B5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/0003-4819-148-9-200805060-00003","article-title":"Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.","volume":"148","author":"Cadarette","year":"2008","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041113223930000_B6","first-page":"CD001983","article-title":"Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis.","volume":"2","author":"Cranney","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2019041113223930000_B7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11587570-000000000-00000","article-title":"Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.","volume":"71","author":"Reginster","year":"2011","journal-title":"Drugs"},{"key":"key\n\t\t\t\t2019041113223930000_B8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrendo.2011.146","article-title":"Antiresorptive therapies for osteoporosis: a clinical overview.","volume":"8","author":"Chen","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"key\n\t\t\t\t2019041113223930000_B9","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2011-3045","article-title":"Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline.","volume":"97","author":"Watts","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113223930000_B10","first-page":"CD000227","article-title":"Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis.","volume":"2","author":"Avenell","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2019041113223930000_B11","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.bone.2011.08.007","article-title":"A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women.","volume":"49","author":"Kumagai","year":"2011","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041113223930000_B12","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00198-011-1786-8","article-title":"Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.","volume":"23","author":"Nakamura","year":"2012","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113223930000_B13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bone.2010.04.594","article-title":"Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.","volume":"47","author":"Genant","year":"2010","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041113223930000_B14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041113223930000_B15","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041113223930000_B16","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t2019041113223930000_B17","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","author":"Hadji","year":"2011","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113223930000_B18","article-title":"Cochrane handbook for systematic reviews of interventions","year":"2008"},{"key":"key\n\t\t\t\t2019041113223930000_B19","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1210\/jc.2007-1907","article-title":"A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system.","volume":"93","author":"Swiglo","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113223930000_B20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"key\n\t\t\t\t2019041113223930000_B21","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019041113223930000_B22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019041113223930000_B23","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons.","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t2019041113223930000_B24","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1359\/jbmr.081214","article-title":"Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.","volume":"24","author":"Boonen","year":"2009","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113223930000_B25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.47276\/lr.77.2.147","article-title":"Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.","volume":"77","author":"Kanaji","year":"2006","journal-title":"Lepr Rev"},{"key":"key\n\t\t\t\t2019041113223930000_B26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00296-008-0689-2","article-title":"Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.","volume":"29","author":"Ringe","year":"2009","journal-title":"Rheumatology International"},{"key":"key\n\t\t\t\t2019041113223930000_B27","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1001\/archinte.165.15.1743","article-title":"Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke.","volume":"165","author":"Sato","year":"2005","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019041113223930000_B28","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer.","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041113223930000_B29","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men.","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113223930000_B30","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.bone.2009.12.034","article-title":"Efficacy and safety of monthly ibandronate in men with low bone density.","volume":"46","author":"Orwoll","year":"2010","journal-title":"Bone"},{"key":"key\n\t\t\t\t2019041113223930000_B31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113223930000_B32","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer.","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113223930000_B33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","article-title":"Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.","volume":"44","author":"Adachi","year":"2001","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041113223930000_B34","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3899\/jrheum.080168","article-title":"Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy.","volume":"35","author":"Okada","year":"2008","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019041113223930000_B35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113223930000_B36","first-page":"8","article-title":"The effect of bisphosphonate on prevention of glucocorticoid-induced osteoporosis.","volume":"10","author":"Saadati","year":"2008","journal-title":"Iranian Red Crescent Med J"},{"key":"key\n\t\t\t\t2019041113223930000_B37","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3899\/jrheum.081207","article-title":"Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.","volume":"36","author":"Stoch","year":"2009","journal-title":"J Rheumatol"},{"key":"key\n\t\t\t\t2019041113223930000_B38","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041113223930000_B39","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.","volume":"15","author":"Reid","year":"2000","journal-title":"J Bone Miner Res"},{"key":"key\n\t\t\t\t2019041113223930000_B40","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","article-title":"Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.","volume":"67","author":"Wallach","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"key\n\t\t\t\t2019041113223930000_B41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00198-007-0505-y","article-title":"Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.","volume":"19","author":"Mok","year":"2008","journal-title":"Osteoporos Int"},{"key":"key\n\t\t\t\t2019041113223930000_B42","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/ard.2010.143453","article-title":"Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.","volume":"70","author":"Mok","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2019041113223930000_B43","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041113223930000_B44","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/art.24879","article-title":"Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.","volume":"60","author":"Saag","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019041113223930000_B45","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/bmj.333.7568.597","article-title":"The case of the misleading funnel plot.","volume":"333","author":"Lau","year":"2006","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019041113223930000_B46","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/jama.294.2.218","article-title":"Contradicted and initially stronger effects in highly cited clinical research.","volume":"294","author":"Ioannidis","year":"2005","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113223930000_B47","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/1471-2474-12-209","article-title":"The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women.","volume":"12","author":"Hopkins","year":"2011","journal-title":"BMC Musculoskelet Disord"},{"key":"key\n\t\t\t\t2019041113223930000_B48","doi-asserted-by":"crossref","first-page":"b5463","DOI":"10.1136\/bmj.b5463","article-title":"Patient level pooled analysis of 68,500 patients from seven major vitamin D fracture trials in US and Europe.","volume":"340","author":"DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) Group","year":"2010","journal-title":"BMJ"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/97\/6\/1871\/10746526\/jcem1871.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T18:04:21Z","timestamp":1641924261000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/97\/6\/1871\/2536568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,1]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2011-3060","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,1]]}}}